drugset / Trial / NCT01908842

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842

Phase 3 Completed 759 enrolled Orexo AB Worldwide Clinical Trials · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to assess retention in treatment after induction with buprenorphine/naloxone (BNX) sublingual tablets compared with generic buprenorphine and after stabilization with BNX sublingual tablets compared with BNX film. Secondary objectives included assessment of treatment effects on opioid withdrawal symptoms, opioid cravings, and safety.

Timeline

Start
2013-08
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified Other
Subject Buprenorphine/naloxone Unknown Other
Subject Buprenorphine/naloxone Unknown Other

Indications